Why an Exton pharma firm will benefit from Almirral's $550M deal with Allergan
Almirall SA has finalized its $550 million acquisition of four approved products and one new drug candidate from Allergan's medical dermatology unit in the United States.
The acquisition bolsters the presence of Almirall, which is based in Barcelona, Spain, in the U.S. dermatology market through its Exton-based subsidiary Aqua Pharmaceuticals.
Almirall acquired Aqua in 2013 in a deal valued at up to $400 million. Aqua makes and markets a variet y of product for skin disorders including acne, eczema,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Acne | Allergy | Biotechnology | Dermatology | Eczema | Health Management | Mergers and Aquisitions | Pharmaceuticals | Skin | Spain Health | USA Health